Objectives: To determine the application of sentinel node biopsy in urothelial carcinoma of the bladder, we performed a systematic review and meta-analysis. Methods: Pooled false negative rate and detection rate were presented using Meta-Disc (version 1.4), and comprehensive meta-analysis (version 2). Publication bias and heterogeneity were assessed using funnel plot, Cochrane Q test, and I2 index. Results: The pooled detection rate was 91% (95% CI 87–93%) and pooled sensitivity was 79% (95% CI 0.69–0.86%). When the neoadjuvant chemotherapy group of patients was omitted, the pooled sensitivity changed to 82% (95% CI 74–88%), and the Cochrane Q and I2 statistics were 15.44 and 48.2%, respectively. The pooled sensitivity of studies that included > 50% of pT 3 or 4 patients was 70% (59–80), by omitting studies that enrolled > 50% of patients at pT stage of 3 or 4, the pooled sensitivity increased to 93% (81–98). Conclusions: Although the studies on SN biopsy of muscle invasive bladder cancer patients resulted in a high detection rate and sensitivity, further validated multicenter trials with larger sample size are essential to confirm the reliability and accuracy of this approach and obtain a standardized method. We showed that pT1 or pT2 bladder cancer patients with clinically negative lymph nodes are the most appropriated group for sentinel lymph node mapping.

Keywords:
Bladder, Cancer, Sentinel lymph mode
1.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer.
Eur Urol
. 2013 Feb; 63(2): 234–41.
2.
Network NCC. NCCN guidelines. 2015.
3.
Karl A, Carroll PR, Gschwend JE, Knüchel R, Montorsi F, Stief CG, et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer.
Eur Urol
. 2009 Apr; 55(4): 826–35.
4.
Cabanas RM. An approach for the treatment of penile carcinoma.
Cancer
. 1977 Feb; 39(2): 456–66.
5.
Ji RC. Lymph Nodes and Cancer Metastasis: New Perspectives on the Role of Intranodal Lymphatic Sinuses.
Int J Mol Sci
. 2016 Dec; 18(1): 51.
6.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al.; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma.
N Engl J Med
. 2014 Feb; 370(7): 599–609.
7.
Ansari M, Rad MA, Hassanzadeh M, Gholami H, Yousefi Z, Dabbagh VR, et al. Sentinel node biopsy in endometrial cancer: systematic review and meta-analysis of the literature.
Eur J Gynaecol Oncol
. 2013; 34(5): 387–401.
8.
Javan H, Gholami H, Assadi M, Pakdel AF, Sadeghi R, Keshtgar M. The accuracy of sentinel node biopsy in breast cancer patients with the history of previous surgical biopsy of the primary lesion: systematic review and meta-analysis of the literature.
Eur J Surg Oncol
. 2012 Feb; 38(2): 95–109.
9.
Sadeghi R, Gholami H, Zakavi SR, Kakhki VR, Tabasi KT, Horenblas S. Accuracy of sentinel lymph node biopsy for inguinal lymph node staging of penile squamous cell carcinoma: systematic review and meta-analysis of the literature.
J Urol
. 2012 Jan; 187(1): 25–31.
10.
Tehranian S, Treglia G, Krag DN, Dabbagh Kakhki VR, Zakavi SR, Sadeghi R, et al. Sentinel node mapping in anal canal cancer: systematic review and meta-analysis.
J Gastrointestin Liver Dis
. 2013 Sep; 22(3): 321–8.
11.
Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, et al.; American Society of Clinical Oncology; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.
J Clin Oncol
. 2012 Aug; 30(23): 2912–8.
12.
Sadeghi R, Treglia G. Systematic reviews and meta-analyses of diagnostic studies: a practical guideline.
Clin Transl Imaging
. 2017; 5(2): 83–7.
13.
Oxford Centre for Evidence-Based Medicine: Levels of Evidence.
14.
DerSimonian R, Laird N. Meta-analysis in clinical trials.
Control Clin Trials
. 1986 Sep; 7(3): 177–88.
15.
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data.
BMC Med Res Methodol
. 2006 Jul; 6(1): 31.
16.
Aljabery F, Shabo I, Olsson H, Gimm O, Jahnson S. Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study.
BJU Int
. 2017 Sep; 120(3): 329–36.
17.
Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Månsson W. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer.
J Urol
. 2006 Jan; 175(1): 84–8.
18.
Manny TB, Hemal AK. Fluorescence-enhanced robotic radical cystectomy using unconjugated indocyanine green for pelvic lymphangiography, tumor marking, and mesenteric angiography: the initial clinical experience.
Urology
. 2014 Apr; 83(4): 824–9.
19.
Marits P, Karlsson M, Sherif A, Garske U, Thörn M, Winqvist O. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes.
Eur Urol
. 2006 Jan; 49(1): 59–70.
20.
Polom W, Markuszewski M, Cytawa W, Czapiewski P, Lass P, Matuszewski M. Fluorescent Versus Radioguided Lymph Node Mapping in Bladder Cancer.
Clin Genitourin Cancer
. 2017 Jun; 15(3):e405–9.
21.
Rosenblatt R, Johansson M, Alamdari F, Sidiki A, Holmström B, Hansson J, et al. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
World J Urol
. 2017 Jun; 35(6): 921–7.
22.
Sherif A, De La Torre M, Malmström PU, Thörn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer.
J Urol
. 2001 Sep; 166(3): 812–5.
23.
Sherif A, Garske U, de la Torre M, Thörn M. Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer.
Eur Urol
. 2006 Jul; 50(1): 83–91.
24.
Roever L. Types of Bias in Studies of Diagnostic Test Accuracy.
Evidence Based Medicine and Practice Open Access Journal
. 2015; 10: 2.
25.
Youssef RF, Raj GV. Lymphadenectomy in management of invasive bladder cancer.
Int J Surg Oncol
. 2011; 2011(Jun): 758189.
26.
Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy.
J Urol
. 2000 Jun; 163(6): 1693–6.
27.
Inoue S, Shiina H, Mitsui Y, Yasumoto H, Matsubara A, Igawa M. Identification of lymphatic pathway involved in the spread of bladder cancer: evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green.
Can Urol Assoc J
. 2013 May-Jun; 7(5-6):E322–8.
28.
Sadeghi R, Hasanzadeh M. Sentinel lymph node biopsy algorithm: can it be a universal method for midline tumors?
Gynecol Oncol
. 2014 Feb; 132(2): 273–4.
29.
Assadi M, Yarani M, Zakavi SR, Jangjoo A, Memar B, Treglia G, et al. Sentinel node mapping in papillary thyroid carcinoma using combined radiotracer and blue dye methods.
Endokrynol Pol
. 2014; 65(4): 281–6.
30.
Hassanzadeh M, Hosseini Farahabadi E, Yousefi Z, Kadkhodayan S, Zarifmahmoudi L, Sadeghi R. Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging.
J Ovarian Res
. 2016 Sep; 9(1): 55.
31.
Zarifmahmoudi L, Sadeghi R. Reliability of the sentinel node mapping according to time from surgery in breast cancer patients with previous excisional biopsy: comment on Sabaté-Llobera et al. study.
Rev Esp Med Nucl Imagen Mol
. 2015 May-Jun; 34(3): 217.
32.
Khadivi E, Daghighi M, Khazaeni K, Dabbagh Kakhki VR, Zarifmahmoudi L, Sadeghi R. Intra-Operative Lymphatic Mapping and Sentinel Node Biopsy in Laryngeal Carcinoma: preliminary Results.
Iran J Otorhinolaryngol
. 2015 Jul; 27(81): 285–91.
33.
Dabbagh Kakhki VR, Bagheri R, Tehranian S, Shojaei P, Gholami H, Sadeghi R, et al. Accuracy of sentinel node biopsy in esophageal carcinoma: a systematic review and meta-analysis of the pertinent literature.
Surg Today
. 2014 Apr; 44(4): 607–19.
34.
Bagheri R, Naghavi F, Kakhki VR, Zakavi SR, Fattahi AS, Jafarian AH, et al. Sentinel node mapping in esophageal squamous cell carcinoma using intra-operative combined blue dye and radiotracer techniques.
Esophagus
. 2013 Dec; 10(4): 211–6.
35.
Fattahi AS, Tavassoli A, Rohbakhshfar O, Sadeghi R, Abdollahi A, Forghani MN. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery?
J Res Med Sci
. 2014 Oct; 19(10): 918–22.
36.
Kadkhodayan S, Shiravani Z, Hasanzadeh M, Sharifi N, Yousefi Z, Fattahi A, et al. Lymphatic mapping and sentinel node biopsy in endometrial cancer—a feasibility study using cervical injection of radiotracer and blue dye. 
Nucl Med Rev Cent East Eur
. 2014; 17(2): 55–8.
37.
Sadeghi R, Alesheikh G, Zakavi SR, Fattahi A, Abdollahi A, Assadi M, et al. Added value of blue dye injection in sentinel node biopsy of breast cancer patients: do all patients need blue dye?
Int J Surg
. 2014; 12(4): 325–8.
38.
Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
J Urol
. 2001 Jul; 166(1): 19–23.
39.
Esplugas S, Bila DM, Krause LG, Dezotti M. Ozonation and advanced oxidation technologies to remove endocrine disrupting chemicals (EDCs) and pharmaceuticals and personal care products (PPCPs) in water effluents.
J Hazard Mater
. 2007 Nov; 149(3): 631–42.
40.
Połom W, Markuszewski M, Cytawa W, Lass P, Matuszewski M. Radio-Guided Lymph Node Mapping in Bladder Cancer Using SPECT/CT and Intraoperative γ-Probe Methods.
Clin Nucl Med
. 2016 Aug; 41(8):e362–7.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.